Triple Negative Breast Cancer News and Research

RSS

Endocyte, Nihon Medi-Physics Collaborate On Companion Imaging Diagnostic

...

6 Sep 2013

Endocyte, Nihon Medi-Physics Collaborate On Companion Imaging Diagnostic

...

6 Sep 2013

Drug to treat blood cancers may also stop spread of invasive breast cancer

A drug used to treat blood cancers may also stop the spread of invasive breast cancer, researchers at Mayo Clinic in Florida have discovered. Their study, published online in Breast Cancer Research, found that in the lab and in animals, the drug decitabine turns on a gene coding for protein kinase D1 (PRKD1) that halts the ability of cancer cells to separate from a tumor and spread to distant organs.

23 Aug 2013

Radiation Oncologist receives Young Investigator Award from PCF

Jefferson Radiation Oncologist, Nicole Simone, M.D., was recently awarded one of 21 Young Investigator Awards from the Prostate Cancer Foundation (PCF).

21 Aug 2013

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

Researchers at The Pennsylvania State University College of Medicine, led by Dr. Ian S. Zagon, have discovered that a novel biological pathway, the OGF-OGFr axis, can be modulated in human triple-negative breast cancer cells to inhibit proliferation. According to BreastCancer.org 1 in 8 women in the U.S. will develop invasive breast cancer and more than 39,000 deaths occur annually.

12 Aug 2013

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

Cancer drugs known as ErbB inhibitors have shown great success in treating many patients with lung, breast, colon and other types of cancer. However, ErbB drug resistance means that many other patients do not respond, and even among those who do, tumors commonly come back.

7 Aug 2013

Research team receives NCI grant to develop precision therapies that kill cancer cells

A research team headed by Fred Hutchinson Cancer Research Center scientists Christopher Kemp, Ph.D., and Carla Grandori, M.D., Ph.D., has received a $4 million grant from the National Cancer Institute to develop precision therapies that selectively kill cancer cells while sparing normal, healthy tissue.

24 Jul 2013

Researchers move closer to specific therapy to treat triple receptor-negative breast cancer

The search for a specific therapy to treat a particularly aggressive type of breast cancer has moved a step forward thanks to new research carried out by the University of Essex.

10 Jun 2013

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, including oncology and companion diagnostics, today announced it treated its first patients in a phase I study of Debio 1143 combined with Carboplatin and Paclitaxel in patients with squamous non-small cell lung cancer, platinum-refractory ovarian cancer, and basal-like/claudin low triple negative breast cancer.

4 Jun 2013

African-American women carry inherited genetic mutations that increase their risk for breast cancer

A high percentage of African-American women with breast cancer who were evaluated at a university cancer-risk clinic were found to carry inherited genetic mutations that increase their risk for breast cancer.

4 Jun 2013

Study finds HER2 irregularities in 14 different advanced solid tumors

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes's expression - among them mutations, amplifications, substitutions, and translocations - have been found in 14 different advanced solid tumors.

3 Jun 2013

Entremed reports patent issuance for its lead drug candidate ENMD-2076

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, today announced the issuance by the Chinese State Intellectual Property Office of Patent Certificate No. ZL 200680044656.7.

7 May 2013

Newly discovered ‘master regulator’ gene may help develop novel treatment for drug-resistant tumors

Researchers at Johns Hopkins have identified a gene that, when repressed in tumor cells, puts a halt to cell growth and a range of processes needed for tumors to enlarge and spread to distant sites. The researchers hope that this so-called "master regulator" gene may be the key to developing a new treatment for tumors resistant to current drugs.

3 May 2013

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Breast cancer brain metastases present a challenge to clinicians because there are few systemic therapies capable of crossing the blood-brain barrier to control the disease.

2 May 2013

Promising development for women with triple-negative breast cancer

Tamoxifen is a time-honored breast cancer drug used to treat millions of women with early-stage and less-aggressive disease, and now a University of Rochester Medical Center team has shown how to exploit tamoxifen's secondary activities so that it might work on more aggressive breast cancer.

24 Apr 2013

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma.

20 Apr 2013

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Recently, doctors have begun to categorize breast cancers into four main groups according to the genetic makeup of the cancer cells. Which category a cancer falls into generally determines the best method of treatment.

16 Apr 2013

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

A dozen Ludwig scientists from around the world presented the latest advancements in basic and clinical cancer research at this week’s American Association for Cancer Research (AACR) Annual Meeting 2013. Progress in immunotherapy and epigenetics led the program with important diagnostic and treatment implications for emerging cancer therapy.

10 Apr 2013

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Researchers from Fox Chase Cancer Center have found that omega-3 fatty acids and their metabolite products slow or stop the proliferation, or growth in the number of cells, of triple-negative breast cancer cells more effectively than cells from luminal types of the disease.

10 Apr 2013

Research: Paragazole makes triple-negative breast cancer cells express estrogen receptors

Breast cancers that lack estrogen receptors are more difficult to treat than ER+ cancers. Research presented at the AACR Annual Meeting 2013 demonstrates an investigational drug, Paragazole, that makes triple-negative breast cancer cells express estrogen receptors, and that increases the sensitivity of these cells to chemotherapy.

9 Apr 2013

Triple Negative Breast Cancer News and Research

Endocyte, Nihon Medi-Physics Collaborate On Companion Imaging Diagnostic

Endocyte, Nihon Medi-Physics Collaborate On Companion Imaging Diagnostic

Drug to treat blood cancers may also stop spread of invasive breast cancer

Radiation Oncologist receives Young Investigator Award from PCF

OGF-OGFr axis can be modulated in human triple-negative breast cancer cells to inhibit proliferation

Combining drugs that target AXL and ErbB receptors could offer better way to fight tumors

Research team receives NCI grant to develop precision therapies that kill cancer cells

Researchers move closer to specific therapy to treat triple receptor-negative breast cancer

Debiopharm evaluates Debio 1143 in combination with Carboplatin and Paclitaxel in NSCLC patients

African-American women carry inherited genetic mutations that increase their risk for breast cancer

Study finds HER2 irregularities in 14 different advanced solid tumors

Entremed reports patent issuance for its lead drug candidate ENMD-2076

Newly discovered ‘master regulator’ gene may help develop novel treatment for drug-resistant tumors

Study shows efficacy of PEGylated liposomal doxorubicin in intracranial model of breast cancer

Promising development for women with triple-negative breast cancer

Monoclonal antibody inhibits tumor growth in angiosarcoma and breast cancer

Researchers develop nanodiamond delivery system for triple-negative breast cancer

Immunotherapy and epigenetics advancements presented by Ludwig at the American Association for Cancer Research

Research shows omega-3 fatty acids stop proliferation of triple-negative breast cancer cells

Research: Paragazole makes triple-negative breast cancer cells express estrogen receptors

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News